



# UNITED STATES LEPARTMENT OF COMMERC

Patent and Trademark Offic

· Washington: D.C., 20231

AND TRADEMARKS

APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. US/642, 406 00/03/76 PIETN | TSRT-154-2

EPI GOOD 193

APRIL C LOGAN
THE SCRIPPS RESEARCH INSTITUTE
OFFICE OF PATENT COUNSEL
10550 NORTH TORREY PINES ROAD
LA JELAA CA 92037

DOCKETED ARTUNIT PAPER NUMB

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademark

**EXHIBIT B** 

	Application No. 08/642,405	Applicant(s) Hein et al.		al.
Office Action Summary	Examiner Thomas Haas		Group Art Unit 1803	
Responsive to communication(s) filed on	·			
☐ This action is FINAL,				
☐ Since this application is in condition for allowance ex in accordance with the practice under Ex parte Quay	ccept for formal matters, rle, 1935 C.D. 11; 453 (	prosecutio D.G. 213.	en as to the me	its is closed
A shortened statutory period for response to this action is longer, from the mailing date of this communication. application to become abandoned. (35 U.S.C. § 133). 37 CFR 1.136(a).	Failure to respond withi	n the perio	d for response v	vill cause the
Disposition of Claims	•		1 1 ×	
X Claim(s) 1-20		is/are	pending In the a	pplication.
Of the above, claim(s)-13-20		is/are w	ithdrawn from o	consideration.
☐ Claim(\$)		(	a/are allowed.	_
		is	/are rejected.	
Claim(s)		le	3/are objected to	<b>)</b> .
☐ Claims	are subject	to restrict	ion or election r	equirement.
☐ The drawing(s) filed on is/ar ☐ The proposed drawing correction, filed on ☐ The specification is objected to by the Examiner. ☐ The oath or declaration is objected to by the Exam	is ⊡app		Hisapproved.	
Priority under 35 U.S.C. § 119  Acknowledgement is made of a claim for foreign All Some* None of the CERTIFIED of received.  received in Application No. (Series Code/Set received in this national stage application for *Certified copies not received:  Acknowledgement is made of a claim for domestic	opies of the priority doc erial Number) om the International Bur	uments hav	ve been  luie 17.2(a)).	
Attachment(s)  Notice of References Cited, PTO-892  Information Disclosure Statement(s), PTO-1449, F Interview Summary, PTO-413  Notice of Draftsperson's Patent Drawing Review, Notice of Informal Patent Application, PTO-152	•			·
CEE DENCE ACTION	041 041 TUE FOLLOWING			

Serial Number: 08/642,406

Page 2

Art Unit: 1803

#### DETAILED ACTION

## Drawings

1. The drawings are objected to for the reasons cited on form PTO 948. Correction is required.

## Double Patenting

2. The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78(d).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 1-12 are rejected under the judicially created doctrine of obviousness-type double patenting as being unparentable over claims 1-11 of U.S. Patent No. 5,639,947. Although the conflicting claims are not identical, they are not patentably distinct from each other because the transgenic plant and method of making same as defined by claims 1-12 of the instant application

6. 2004 8: 24PM scripps Rassauch Institute Under LARDNER

Serial Number: 08/642,406

Art Unit: 1803

Page 3

are encompassed by claims 1-11 of U.S. Patent No. 5,639,947. One of ordinary skill in the art would recognize that the number of plants trassformed with the particular nucleotide sequences of the invention is an optimization of design parameters as these plants are to be sexually crossed and selected and thereby the resulting transgenic plants would comprise the desired heterologous nucleotide sequences.

#### Conclusion

4. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thomas Haas whose telephone number is (703) 305-7270. The examiner can normally be reached on Mon.-Fri. from 7:00 to 4:30.

If anymors to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Doug Robinson, can be reached on (703) 308-2897. The fax phone number for this Group is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.